Abstract Number: 476 • 2015 ACR/ARHP Annual Meeting
Clinical Disease Activity Measures Change Substantially and Irregularly over Time in Individual Rheumatoid Arthritis Patients Considered to be in Steady State
Background/Purpose: Assessment of clinical markers of disease activity is routine in monitoring patients with rheumatoid arthritis (RA) in daily practice. Changes in clinical measures may…Abstract Number: 477 • 2015 ACR/ARHP Annual Meeting
On-Demand Use of Etanercept Only for Disease Flares Reduced the Disease Activity Score and Structural Damage Equivalent to Fully-Use of Etanercept in RA Patients
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) are essential in the treatment of rheumatoid arthritis (RA). Biological DMARDs are particularly recommended for patients with active RA…Abstract Number: 478 • 2015 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients
Background/Purpose: The multi-biomarker disease activity (MBDA) score [Vectra] has been evaluated in a number of settings, yet has only limited data evaluating whether it is…Abstract Number: 479 • 2015 ACR/ARHP Annual Meeting
How to Recruit Anti-CCP Positive Patients from Primary Care
Background/Purpose: Around 1% of the population test positive for anti-cyclic citrullinated peptide (anti-CCP) antibodies. This biomarker predicts progression to rheumatoid arthritis (RA) but over a…Abstract Number: 480 • 2015 ACR/ARHP Annual Meeting
Comparative 10-Year Retention Rates of Adalimumab Used in Mono and Combination Therapy in Rheumatoid Arthritis (RA) Patients from the Rhumadata Clinical Database and Registry
Background/Purpose: The recent publication of the concerto trial comparing the use of adalimumab in monotherapy versus in association with methotrexate (MTX) at dose varying from…Abstract Number: 481 • 2015 ACR/ARHP Annual Meeting
Time to Disease-Modifying Anti-Rheumatic Drug Treatment for New Patients with Rheumatoid Arthritis – Single Center Experience
Background/Purpose: In early rheumatoid arthritis (RA), initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset is associated with a significant benefit in…Abstract Number: 482 • 2015 ACR/ARHP Annual Meeting
Erosions in the Foot at Baseline Are Predictive of Orthopedic Shoe Use after 10 Years of Treat to Target Therapy
Background/Purpose: Orthopaedic shoes (OS) may help to reduce pain and increase activity participation in rheumatoid arthritis (RA) patients, but should ideally not be needed. We…Abstract Number: 483 • 2015 ACR/ARHP Annual Meeting
Antibody to Malondialdehyde-Acetaldehyde (MAA) Adducts Serve As Biomarkers of Treatment Response in Rheumatoid Arthritis
Background/Purpose: Previous reports have demonstrated that malondialdehyde-acetaldehyde (MAA) adducts are produced as a byproduct of oxidative stress and lipid peroxidation and are expressed in…Abstract Number: 484 • 2015 ACR/ARHP Annual Meeting
Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use
Background/Purpose: Despite remarkable improvements in RA treatment, there is evidence indicating that the mortality gap between RA patients and the general population is not closing.…Abstract Number: 485 • 2015 ACR/ARHP Annual Meeting
Evaluate the Dose Efficacy Response Relationship of Baricitinib in Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib (Bari) is an oral inhibitor of Janus kinases (JAK) selective for JAK 1 and 2. It has demonstrated dose-dependent efficacy in patients with…Abstract Number: 486 • 2015 ACR/ARHP Annual Meeting
Persistence Among Rheumatoid Arthritis Patients Initiating Intravenous or Subcutaneous Anti-Tumor Necrosis Factor Therapy in a Large US Registry Cohort
Background/Purpose: The objective of this analysis was to examine persistence with intravenous (IV) and subcutaneous (SC) anti-TNF therapies among rheumatoid arthritis (RA) patients (pts) within…Abstract Number: 487 • 2015 ACR/ARHP Annual Meeting
Early Rheumatoid Arthritis Patients in the Worse Disease Trajectory Group Fail to Achieve Improvement in Physical Function
Background/Purpose: Disease trajectories in early rheumatoid arthritis (ERA) are characterized by differences in absolute levels of disease activity and rates of improvement, with patients in…Abstract Number: 488 • 2015 ACR/ARHP Annual Meeting
Six-Year Retention Rates with Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry
Background/Purpose: The sustainability of any regimen is an important factor to consider when selecting therapy for chronic conditions, such as rheumatoid arthritis (RA). Recent reports…Abstract Number: 489 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Toxicity of Methotrexate Monotherapy in Daily Clinical Practice. Results from an Early Arthritis Clinic
Background/Purpose: Several trials had reported the efficacy and toxicity of methotrexate monotherapy in patients with early rheumatoid arthritis. However, patients outside clinical trials could be…Abstract Number: 490 • 2015 ACR/ARHP Annual Meeting
Personalizing the Treat to Target Approach in Rheumatoid Arthritis
Background/Purpose: The treat to target (T2T) approach has become part of the standard of care in RA management. Implicit in this approach is patient involvement…
ACR Meeting Abstracts